{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:42:36Z","timestamp":1792190556320,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The incidence of papillary thyroid carcinoma (PTC) has been steadily increasing over the past decades. Hashimoto\u2019s thyroiditis (HT) is the most common autoimmune disease, and is related to the pathogenesis of PTC. Programmed death-1 (PD-1) is currently used for the treatment of PTC, but there are very few studies on the clinical value of PD-1 in the diagnosis and targeted therapy of PTC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The expression of T, B, NK cells and PD-1 in the peripheral blood of 132 patients with PTC (PTC group), 48 patients with nodular goiter (NG group) and 63 healthy subjects (HP group) were detected by flow cytometry. The expression of plasma T3, T4, FT3, FT4, TSH, TGAb and TPO was detected by chemiluminescence immunoassay. Among 132 PTC, 49 PTC&amp;HT and 83 PTC&amp;noHT were included. Among 48 NG, 10 NG&amp;HT and 38 NG&amp;noHT were included. The expressions of programmed death- ligand1(PD-L1) in tumor tissues of PTC group and thyroid tissues of NG group, PD-1 and CD3 in tumor infiltration lymphocyte (TIL) were detected by immunohistochemistry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The expression of FT3, TGAb, CD3<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup>, CD3<jats:sup>+<\/jats:sup>CD4<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup> and CD3<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup> in PTC and NG was significantly higher than that in the HP group. Moreover, CD3<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup>, CD3<jats:sup>+<\/jats:sup>CD4<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup> and CD3<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup> expression had significant differences between the PTC group and the NG group. In addition, the expression of TGAb, TPO, CD3<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup>, CD3<jats:sup>+<\/jats:sup>CD4<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup> and CD3<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup> in PTC&amp;HT group was significantly higher than that in the PTC&amp;noHT group. While, the expression of B cells, CD3<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup>, CD3<jats:sup>+<\/jats:sup>CD4<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup> and CD3<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup> in PTC&amp;HT group was higher than that in NG&amp;HT group. PD-1 showed a significant correlation with PTC lymph node metastasis. CD3<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup> and CD3<jats:sup>+<\/jats:sup>CD4<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup> was higher in N1 stage than in N0 stage. Immunohistochemical results showed that the expression of PD-1, CD3 and PD-L1 in PTC was significantly higher than that in NG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>T cell exhaustion might act as a biomarker for the differential diagnosis of PTC and NG. Patients with PTC&amp;HT have obvious T cell exhaustion and increased expression of PD-1, PD-L1.Targeting the PD-1\/PD-L1 pathway could be a new approach to prevent malignant transformation from HT to PTC&amp;HT in the future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13000-021-01139-7","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T18:03:28Z","timestamp":1630433008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis"],"prefix":"10.1186","volume":"16","author":[{"given":"Chumeng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuechu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-6859","authenticated-orcid":false,"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"1139_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.","DOI":"10.3322\/caac.21660"},{"issue":"6","key":"1139_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"23","key":"1139_CR3","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMc1609116","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid Cancer. N Engl J Med. 2016;375(23):2307.","journal-title":"N Engl J Med"},{"issue":"1","key":"1139_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ecl.2018.10.002","volume":"48","author":"CD Seib","year":"2019","unstructured":"Seib CD, Sosa JA. Evolving understanding of the epidemiology of thyroid Cancer. Endocrinol Metab Clin N Am. 2019;48(1):23\u201335.","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"22","key":"1139_CR5","first-page":"7778","volume":"22","author":"R Zeng","year":"2018","unstructured":"Zeng R, Zhao M, Niu H, et al. Relationship between Hashimoto's thyroiditis and papillary thyroid carcinoma in children and adolescents. Eur Rev Med Pharmacol Sci. 2018;22(22):7778\u201387.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"1139_CR6","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1089\/thy.2019.0726","volume":"30","author":"EA Basak","year":"2020","unstructured":"Basak EA, van der Meer JWM, Hurkmans DP, et al. Overt thyroid dysfunction and anti-thyroid antibodies predict response to anti-PD-1 immunotherapy in Cancer patients. Thyroid. 2020;30(7):966\u201373.","journal-title":"Thyroid"},{"issue":"4","key":"1139_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN. T cell dysfunction in Cancer. Cancer Cell. 2018;33(4):547\u201362.","journal-title":"Cancer Cell"},{"issue":"6","key":"1139_CR8","doi-asserted-by":"publisher","first-page":"E934","DOI":"10.1210\/jc.2011-3428","volume":"97","author":"JD French","year":"2012","unstructured":"French JD, Kotnis GR, Said S, et al. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab. 2012;97(6):E934\u201343.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1139_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12022-018-9540-9","volume":"29","author":"D Lubin","year":"2018","unstructured":"Lubin D, Baraban E, Lisby A, et al. Papillary thyroid carcinoma emerging from Hashimoto thyroiditis demonstrates increased PD-L1 expression, which persists with metastasis. Endocr Pathol. 2018;29(4):317\u201323.","journal-title":"Endocr Pathol"},{"key":"1139_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.oraloncology.2018.01.021","volume":"78","author":"HI Kim","year":"2018","unstructured":"Kim HI, Kim K, Park SY, et al. Refining the eighth edition AJCC TNM classification and prognostic groups for papillary thyroid cancer with lateral nodal metastasis. Oral Oncol. 2018;78:80\u20136.","journal-title":"Oral Oncol"},{"issue":"6230","key":"1139_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74\u201380.","journal-title":"Science"},{"key":"1139_CR12","doi-asserted-by":"crossref","unstructured":"Ferrari SM, Fallahi P, Galdiero MR, Ruffilli I, Elia G, Ragusa F, Paparo SR, Patrizio A, Mazzi V, Varricchi G, Marone G, Antonelli A. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. Int J Mol Sci. 2019;20(18):4413.","DOI":"10.3390\/ijms20184413"},{"issue":"1","key":"1139_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310.","journal-title":"Immunity"},{"issue":"1","key":"1139_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13000-020-00931-1","volume":"15","author":"H Lu","year":"2020","unstructured":"Lu H, Zhang L, Dai Y, et al. Markers of immune activation: novel biomarkers to predict the early-warning indicator of patients with papillary thyroid carcinoma. Diagn Pathol. 2020;15(1):16.","journal-title":"Diagn Pathol"},{"issue":"5","key":"1139_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765\u201372.","journal-title":"Int Immunol"},{"key":"1139_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"7528","key":"1139_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"1","key":"1139_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24\u201333.","journal-title":"Trends Mol Med"},{"issue":"3","key":"1139_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, et al. Mechanisms controlling PD-L1 expression in Cancer. Mol Cell. 2019;76(3):359\u201370.","journal-title":"Mol Cell"},{"key":"1139_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","volume":"224","author":"BT Fife","year":"2008","unstructured":"Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166\u201382.","journal-title":"Immunol Rev"},{"issue":"1","key":"1139_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1084\/jem.20022119","volume":"198","author":"AD Salama","year":"2003","unstructured":"Salama AD, Chitnis T, Imitola J, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med. 2003;198(1):71\u20138.","journal-title":"J Exp Med"},{"issue":"19","key":"1139_CR22","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-18-0205","volume":"24","author":"T Kato","year":"2018","unstructured":"Kato T, Noma K, Ohara T, et al. Cancer-associated fibroblasts affect Intratumoral CD8(+) and FoxP3(+) T cells via IL6 in the tumor microenvironment. Clin Cancer Res. 2018;24(19):4820\u201333.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1139_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1530\/ERC-11-0028","volume":"18","author":"E Fiore","year":"2011","unstructured":"Fiore E, Rago T, Latrofa F, et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer. 2011;18(4):429\u201337.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1139_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4254\/wjh.v7.i3.327","volume":"7","author":"C Ferri","year":"2015","unstructured":"Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. World J Hepatol. 2015;7(3):327\u201343.","journal-title":"World J Hepatol"},{"issue":"3","key":"1139_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.prp.2016.12.022","volume":"213","author":"W Li","year":"2017","unstructured":"Li W, Ming H, Sun D, et al. The relationship between BRAFV600E, NF-kappaB and TgAb expression in papillary thyroid carcinoma. Pathol Res Pract. 2017;213(3):183\u20138.","journal-title":"Pathol Res Pract"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-021-01139-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-021-01139-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-021-01139-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T18:05:45Z","timestamp":1630433145000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-021-01139-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1139"],"URL":"https:\/\/doi.org\/10.1186\/s13000-021-01139-7","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Ethics Committee of Taizhou Central Hospital. Written informed consent was obtained from each individual in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}